Here’s what you need to know:
– Inato, a technology platform that connects pharma companies (trial sponsors) with community-based trial sites raises $20M in new funding (A2) led by Cathay Innovation with participation from existing investor Obvious Ventures and new investors La Maison and Top Harvest Capital. Inato partners with over 30 top pharmaceutical companies to make clinical trials more inclusive.
– The new funding will fuel Inato’s continued product innovation, international growth, and hiring of top talent. Inato will increase its diversity product offering in order to allow sponsors to meet their diversity goals. This is based upon new FDA requirements.
– Inato will also invest in oncology-specific innovation to increase access to care where, despite the number of oncology studies increasing at almost twice the pace of any other therapeutic area, enrollment rates remain startlingly low. Inato will continue to refine and scale its data model in order to increase the reliability of matching between sponsor trials and community sites.
